The most relevant factor in deciding on monoclonal antibody therapy is whether it is active against the currently circulating strains of COVID-19. The WHO and NICE both advise that the choice of a neutralizing monoclonal antibody may depend on emerging data on effectiveness of different antibodies against different SARS-CoV-2 variants.
Molnupiravir therapy is initiated at home within a few hours of the video visit. The patient begins to experience improvement in symptoms within a few days and tests negative by rapid antigen test 6 days after receiving therapy.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Enrico Brunetti. Skill Checkup: A 68-Year-Old Woman With Low-Grade Fever, Headache, Body Aches, Fatigue, Nasal Congestion, and Sore Throat - Medscape - Nov 07, 2022.